StockData
Protara Therapeutics, Inc. logo

Protara Therapeutics, Inc. (TARA) stock

TARANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/30
$2.32−0.06 (-2.52%)

Close on Nov 17, 2026Market cap $137.10MP/E –Yield –

Protara Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Protara Therapeutics's enterprise value was $12.31M on Nov 11, 2026, against $151.36M a year earlier. Over the last 5 years it ranged from -$69.53M to $185.26M, with a median of -$32.46M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$12.31M-83.0%
2025Dec 31, 2025$72.26M+170.8%
2024Dec 31, 2024$26.68M–
2023Dec 29, 2023-$53.47M–
2022Dec 30, 2022-$66.87M–
2021Dec 31, 2021-$17.92M-120.1%
2020Dec 31, 2020$89.20M–
2019Dec 31, 2019-$1.27M-107.3%
2018Dec 31, 2018$17.43M–
2017Dec 29, 2017-$13.92M–
2016Dec 30, 2016-$15.49M-108.4%
2015Dec 31, 2015$185.10M–
2014Dec 31, 2014-$19.20M–

More Protara Therapeutics figures

See a number that looks wrong?